Spots Global Cancer Trial Database for Study of DMXAA (Now Known as ASA404) in Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of DMXAA (Now Known as ASA404) in Solid Tumors
Official Title: Phase I Trial of 5,6 Dimethylxanthenone - 4 - Acetic Acid (DMXAA) in Solid Tumors
Study ID: NCT00863733
Conditions
Interventions
Study Description
Brief Summary: This is a phase I study aimed at identifying safe doses of DMXAA in patients with solid tumors.
Detailed Description: This is a dose escalation study conducted at a single center in New Zealand. Patients received dimethylxanthenone acetic acid (DMXAA) IV over 20 minutes once every three weeks, up to a maximum of 12 courses. Cohorts of 3 patients received escalated doses of DMXAA until the maximum tolerated dose (MTD) was determined. The MTD is defined as the dose preceding that at which 2 of 3 patients experience dose limiting toxicity. Patients had solid tumors for which there was no standard therapy or were refractory to conventional therapy.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Dr Paul Thompson
Affiliation: Auckland Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
